| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 2001;72:1160-1164
© 2001 The Society of Thoracic Surgeons
a Department of Thoracic Surgery, Askepios Fachkiniken Müchen-Gauting, University of Munich, Munich, Germany
b Department of Pathology, Asklepios Fachkliniken München-Gauting, Munich, Germany
c Department of Surgery, University of Munich, Munich, Germany
Address reprint requests to Dr Passlick, Department of Surgery, University of Munich, Klinikum Innenstadt, Nussbaumstr 20, 80336 Munich, Germany
e-mail: passlick{at}lrz.uni-muenchen.de
Presented at the Poster Session of the Thirty-seventh Annual Meeting of The Society of Thoracic Surgeons, New Orleans, LA, Jan 29–31, 2001.
Background. Treatment options for patients with microscopic residual disease at the bronchial margin (R1-resection) after resection for non-small cell lung cancer include observation, radiotherapy, reoperation, or even systemic therapy. The present study was performed to identify a parameter that would estimate the prognosis of these patients more precisely to permit a well-founded treatment recommendation for the individual patient.
Methods. A total of 1,162 patients with resected nonsmall cell lung cancer were analyzed in this retrospective study. Fifty-four patients (4.6%) had R1-resections at the bronchial margin. Type of residual disease (mucosal, extramucosal, or involvement of the entire bronchial wall) and occurrence of tumor cells in the lymphatic vessels (lymphangiosis carcinomatosa) were recorded as distinct parameters and analyzed by univariate and multivariate analyses (Log rank test; Cox regression model).
Results. Lymphangiosis carcinomatosa at the bronchial margin was detected in 22 patients (40.7%) and was associated with a significantly shortened survival (median survival with lymphangiosis carcinomatosa, 13.3 months; without lymphangiosis carcinomatosa, 20.1 months; p = 0.026). Early stage patients (stage I–II) without lymphangiosis carcinomatosa showed a median survival of 49 months. Multivariate analysis revealed that lymphangiosis carcinomatosa at the resection margin is an independent prognostic parameter (p = 0.038). Even after postoperative radiotherapy the prognosis was still poor if a lymphangiosis carcinomatosa was detected (median survival, 17.1 months). All other parameters (T-stage, N-stage, tumor histology, type of bronchial wall involvement) were not of prognostic significance in R1-resected patients.
Conclusions. Lymphangiosis carcinomatosa at the bronchial resection margin predicts a poor prognosis in patients with non-small cell lung cancer. It is more than questionable whether these patients would benefit from local treatment options like radiotherapy.
This article has been cited by other articles:
|
|
 |
|
  E. Fernandez, P. L. de Castro, J. Astudillo, J. Fernandez-Llamazares, and and GCCB-S (Bronchogenic Carcinoma Cooperative Gro Bronchial stump infiltration after lung cancer surgery. Retrospective study of a series of 2994 patients Interactive CardioVascular and Thoracic Surgery, August 1, 2009; 9(2): 182 - 186. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wind, E. J. Smit, S. Senan, and J.-P. Eerenberg Residual disease at the bronchial stump after curative resection for lung cancer Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 29 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Guo, M. G. House, C. Hooker, Y. Han, E. Heath, E. Gabrielson, S. C. Yang, S. B. Baylin, J. G. Herman, and M. V. Brock Promoter Hypermethylation of Resected Bronchial Margins: A Field Defect of Changes? Clin. Cancer Res., August 1, 2004; 10(15): 5131 - 5136. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
